Geoffrey von MaltzahnFounder

United States - Cambridge, Massachusetts,

Inventor, entrepreneur, and founder of life science companies to solve important challenges in healthcare, nutrition, and agriculture.

Founder of startups that have achieved over $10 billion in public and private market capitalization. These include Tessera Therapeutics, Generate Biomedicines, Indigo Agriculture, Sana Biotechnology (SANA), Cobalt Biomedicine (acquired by Sana), Kaleido Biosciences (NASDAQ: KLDO), Seres Therapeutics (NASDAQ: MCRB), and Axcella Health (NASDAQ: AXLA), which respectively are pioneering gene writing, generative biology, plant microbiome products for crop improvement, engineered cells as medicine, cell-specific gene therapies, novel chemistries to drug the human microbiome, microbiome therapeutics, and amino acid-based drugs.

General Partner in Flagship Pioneering, CEO of Tessera Therapeutics, CEO of Generate Biomedicines, and CIO of Indigo. Recently served as CEO of Cobalt Biomedicine from inception to merger with Sana Biotechnology; CEO of Kaleido Biosciences through launch of multiple clinical programs; and CEO of Indigo building the company's platform and led the development of Indigo Cotton and Wheat commercial products. He was previously CTO of Seres Therapeutics, where he led the discovery of SER-109, and VP, Discovery of Axcella Health.

Inventor on over 200 patent applications and patents, co-author of 20 peer-reviewed publications, and recipient of over 20 awards and honors, including Business Insider's 30 under 40 young leaders, Endpoints 20 under 40, and the prestigious Lemelson-MIT Student Prize for invention and innovation. Geoff also has had his inventions recognized by the World Economic Forum, Forbes, CNN, Technology Review, Bloomberg, among the “greatest scientific breakthroughs of today” by Dean Kamen on Planet Green, and in the Innovations of the Year by MSNBC.